MC-Rx
Powered by ProCare Rx

Epogen®

Ticket #: _____ **Request Date:** _____ **Request Time:** _____

Epogen® Prior Authorization Request Form (Page 1 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)

Member Name:		
Insurance ID#:		
Date of Birth:		
Street Address:		
City:	State:	Zip:
Phone:		

Provider Information (required)

Provider Name:		
NPI#:	Specialty:	
Office Phone:		
Office Fax:		
Office Street Address:		
City:	State:	Zip:

Medication Information (required)

Medication Name:	Strength:	Dosage Form:
❑ Check if requesting **brand**	Directions for Use:	
❑ Check if request is for **continuation of therapy**		

Clinical Information (required)

Select the diagnosis below:

- ❑ Anemia due to chronic kidney disease
- ❑ Anemia in cancer patients on chemotherapy
- ❑ Anemia in hepatitis C virus (HCV)-infected patients due to ribavirin in combination with interferon or peg-interferon
- ❑ Anemia in HIV-infected patients
- ❑ Anemia in patients with myelodysplastic syndrome (MDS)
- ❑ Preoperative use for reduction of allogeneic blood transfusion in patients undergoing surgery
- ❑ Other diagnosis: _____ ICD-10 Code(s): _____

Medication History:

Is this request for continuation of Epogen therapy? ❑ **Yes** ❑ **No**

Does the patient have history of failure, contraindication, or intolerance to Aranesp? ❑ **Yes** ❑ **No**

Does the patient have history of failure, contraindication, or intolerance to Procrit? ❑ **Yes** ❑ **No**

For anemia due to chronic kidney disease, answer the following:

Is the patient on dialysis? ❑ **Yes** ❑ **No**

Has the patient been evaluated for adequate iron stores? ❑ **Yes** ❑ **No**

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within ***30 days*** of this request:

Hemoglobin (Hgb): _____ Date: _____ Hematocrit (Hct): _____ Date: _____

Does the rate of hemoglobin decline indicate the likelihood of requiring a red blood cell (RBC) transfusion? ❑ **Yes** ❑ **No**

Is the goal of therapy to reduce the risk of alloimmunization and/or other RBC transfusion-related risks? ❑ **Yes** ❑ **No**

Reauthorization:

Has the patient been evaluated for adequate iron stores? ❑ **Yes** ❑ **No**

Is there a decrease in the need for blood transfusion with Epogen therapy? ❑ **Yes** ❑ **No**

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level? ❑ **Yes** ❑ **No**

Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months:

Hgb: _____ Hct: _____ Date: _____

Hgb: _____ Hct: _____ Date: _____

Hgb: _____ Hct: _____ Date: _____

Epogen® Prior Authorization Request Form (Page 2 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For anemia in cancer patients on chemotherapy, answer the following:

Have all other causes of anemia been ruled out? ❑ **Yes** ❑ **No**

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within ***the prior two weeks*** of this request:

Hemoglobin (Hgb): _____ Date: _____ Hematocrit (Hct): _____ Date: _____

Has the patient been evaluated for adequate iron stores? ❑ **Yes** ❑ **No**

Is the cancer a non-myeloid malignancy? ❑ **Yes** ❑ **No**

Is the patient concurrently on chemotherapy? ❑ **Yes** ❑ **No**

Will the patient be receiving concomitant chemotherapy for a minimum of 2 months? ❑ **Yes** ❑ **No**

Is the anemia caused by cancer chemotherapy? ❑ **Yes** ❑ **No**

Reauthorization:

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within ***the prior two weeks*** of this request:

Hemoglobin (Hgb): _____ Date: _____ Hematocrit (Hct): _____ Date: _____

Is there a decrease in the need for blood transfusion with Epogen therapy? ❑ **Yes** ❑ **No**

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level? ❑ **Yes** ❑ **No**

Is the patient concurrently on chemotherapy? ❑ **Yes** ❑ **No**

Will the patient be receiving concomitant chemotherapy for a minimum of 2 months? ❑ **Yes** ❑ **No**

Is the anemia caused by cancer chemotherapy? ❑ **Yes** ❑ **No**

For anemia in HCV-infected patients due to ribavirin in combination with interferon or peg-interferon, answer the following:

Does the patient have a diagnosis of hepatitis C virus (HCV) infection? ❑ **Yes** ❑ **No**

Has the patient been evaluated for adequate iron stores? ❑ **Yes** ❑ **No**

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within ***30 days*** of this request:

Hemoglobin (Hgb): _____ Date: _____ Hematocrit (Hct): _____ Date: _____

Is the patient receiving ribavirin? ❑ **Yes** ❑ **No**

Is the patient receiving interferon alfa-2b, interferon alfacon-1, peginterferon alfa-2b, or peginterferon alfa-2a? ❑ **Yes** ❑ **No**

Reauthorization:

Is there a decrease in the need for blood transfusion with Epogen therapy? ❑ **Yes** ❑ **No**

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level? ❑ **Yes** ❑ **No**

Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months:

Hgb: _____ Hct: _____ Date: _____

Hgb: _____ Hct: _____ Date: _____

Hgb: _____ Hct: _____ Date: _____

For anemia in HIV-infected patients, answer the following:

Has the patient been evaluated for adequate iron stores? ❑ **Yes** ❑ **No**

Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within ***30 days*** of this request:

Hemoglobin (Hgb): _____ Date: _____ Hematocrit (Hct): _____ Date: _____

Is the serum erythropoietin level less than or equal to 500 mU/mL? ❑ **Yes** ❑ **No**

Is the patient receiving zidovudine (AZT) therapy? ❑ **Yes** ❑ **No**

Does the patient have a diagnosis of HIV infection? ❑ **Yes** ❑ **No**

Reauthorization:

Is there a decrease in the need for blood transfusion with Epogen therapy? ❑ **Yes** ❑ **No**

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level? ❑ **Yes** ❑ **No**

Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months:

Hgb: _____ Hct: _____ Date: _____

Hgb: _____ Hct: _____ Date: _____

Hgb: _____ Hct: _____ Date: _____

Epogen® Prior Authorization Request Form (Page 3 of 3)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For preoperative use for reduction of allogeneic blood transfusion in patients undergoing surgery, answer the following:

Is the patient scheduled to undergo elective, non-cardiac, non-vascular surgery? ❑ **Yes** ❑ **No**

Is the hemoglobin (Hgb) > 10 to ≤ 13 g/dL? ❑ **Yes** ❑ **No**

Is the patient at high risk for perioperative transfusions? ❑ **Yes** ❑ **No**

Is the patient willing or able to donate autologous blood pre-operatively? ❑ **Yes** ❑ **No**

Has the patient been evaluated for adequate iron stores? ❑ **Yes** ❑ **No**

For anemia in patients with myelodysplastic syndrome (MDS), answer the following:

Is the serum erythropoietin level less than or equal to 500 mU/mL? ❑ **Yes** ❑ **No**

Does the patient have transfusion-dependent MDS? ❑ **Yes** ❑ **No**

Has the patient been evaluated for adequate iron stores? ❑ **Yes** ❑ **No**

Reauthorization:

Is there a decrease in the need for blood transfusion with Epogen therapy? ❑ **Yes** ❑ **No**

Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level? ❑ **Yes** ❑ **No**

Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months:

Hgb: _____ Hct: _____ Date: _____

Hgb: _____ Hct: _____ Date: _____

Hgb: _____ Hct: _____ Date: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Authorized Medical Signature:	
Telephone:	**Date:**

When Completed Return To:

MC-Rx Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507
1-866-965-Drug (3784) / Fax # 866-999-7736

Please note: This request may be denied unless all required information is received.